To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-01-11

No results posted yet for this study

Summary

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Conditions

  • Amphetamine-Related Disorders

Interventions

DRUG

Lobeline

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Reese Jones, M.D. · Langley Porter Psychiatric Institute

Study Design

Purpose
DIAGNOSTIC

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100074 on ClinicalTrials.gov